COMMUNITY CLINICAL ONCOLOGY PROGRAM

Summary

Principal Investigator: C L Loprinzi
Affiliation: Mayo Clinic
Country: USA
Abstract: DESCRIPTION: (Applicant's Description) The Mayo Clinic, through the vehicle of the North Central Cancer Treatment Group (NCCTG), will serve as a primary research base for the following 15 CCOPs: Ann Arbor Regional CCOP, Carle Cancer Center CCOP, Cedar Rapids Oncology Project CCOP, Des Moines CCOP, Duluth CCOP, Merit Care Hospital CCOP, Geisinger CCOP, Metro Minnesota CCOP, Missouri Valley Cancer Consortium CCOP, Ochsner Clinic CCOP, Illinois Oncology Research Association CCOP, Scottsdale CCOP, Siouxland Community Cancer Consortium CCOP, Toledo CCOP, and the Wichita CCOP. We will also serve as a research base for cancer control protocol activity of non-CCOP participants and for the multiple CCOPs outside of our group who contribute to intergroup cancer treatment and cancer control protocols which we lead. We will cooperate with our affiliated CCOPs in planning their program and in conducting appropriate continuing education and workshops. We will provide training and active support for their data managers and oncology nurses. We will coordinate their multidisciplinary involvement in clinical cancer research protocols. This will include evolving and maintaining standard reporting procedures for surgery, pathology, and radiation therapy. We will hold regular meetings of the CCOPs for review of ongoing research, planning future research, and for related professional activities. We will continue the rigid quality control procedures which have proved so successful in the past, and upgrade these procedures as indicated. We will constantly monitor CCOP performance not only by timely review of patients, data sheets, pathology material, operative reports, and radiation therapy port films, but also by periodic randomly scheduled monitoring site visits. We will work with each CCOP participant to aid in their maturation as clinical investigators. We will assist them in developing new protocols for which they will share leadership, and we will work with them in preparing publications as well as presentations for national and regional meetings. We will make every effort to provide them with justifiable pride in their participation in the National Cancer Program. A high priority over this grant period will be the further expansion of our cancer control efforts with incorporation of associated basic laboratory support, leading to scientifically rigorous translational research efforts.
Funding Period: 1983-09-15 - 2007-05-31
more information: NIH RePORT

Top Publications

  1. ncbi Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials
    Aminah Jatoi
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Int J Oncol 36:601-6. 2010
  2. ncbi Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group
    Thomas E Witzig
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1074-80. 2008
  3. ncbi Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)
    Aminah Jatoi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 113:847-53. 2008
  4. ncbi Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group
    David J Inwards
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 113:108-16. 2008
  5. ncbi A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021
    Scott H Okuno
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 112:1772-9. 2008
  6. ncbi Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)
    Elizabeth A Johnson
    Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Lung Cancer 60:200-7. 2008
  7. ncbi Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044)
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 30:507-13. 2007
  8. ncbi Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741
    Grace K Dy
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 25:3469-74. 2007
  9. ncbi A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 110:1396-403. 2007
  10. ncbi Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53)
    Steven E Schild
    Mayo Clinic Arizona, Department of Radiation Oncology, Scottsdale, AZ 85259, USA
    J Clin Oncol 25:3124-9. 2007

Scientific Experts

Detail Information

Publications62

  1. ncbi Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials
    Aminah Jatoi
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Int J Oncol 36:601-6. 2010
    ..Although age should not preclude trial entry, these adverse event rates suggest a need to develop more tolerable regimens for older patients with these malignancies...
  2. ncbi Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group
    Thomas E Witzig
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1074-80. 2008
    ..3 months (95% CI: 5.3-14.0), the median event-free survival (EFS) was 5.3 months (95% CI: 3.9-11.0), and the median overall survival was 30.5 months (95% CI: 17.8-60.6). We conclude that rituximab can be safely added to standard DHAP...
  3. ncbi Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)
    Aminah Jatoi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 113:847-53. 2008
    ..Epidermal growth factor receptor (EGFR) inhibitors are effective cancer therapies, but they are reported to cause a rash in >50% of patients. In the current study, the authors examined the use of tetracycline for rash prevention...
  4. ncbi Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group
    David J Inwards
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 113:108-16. 2008
    ..The objective of this study was to test cladribine (2-CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL)...
  5. ncbi A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021
    Scott H Okuno
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 112:1772-9. 2008
    ....
  6. ncbi Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)
    Elizabeth A Johnson
    Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Lung Cancer 60:200-7. 2008
    ....
  7. ncbi Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044)
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 30:507-13. 2007
    ..This study tested a 3-drug, multimodality approach. Chemotherapy dose reductions, the addition of amifostine, and pharmacogenetics were tested in an effort to mitigate toxicity and predict outcomes...
  8. ncbi Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741
    Grace K Dy
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 25:3469-74. 2007
    ..To evaluate clinical characteristics and survival outcomes among patients with locally advanced or metastatic colorectal cancer who achieve a complete response (CR) to systemic treatment either alone or with multimodality approach...
  9. ncbi A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 110:1396-403. 2007
    ....
  10. ncbi Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53)
    Steven E Schild
    Mayo Clinic Arizona, Department of Radiation Oncology, Scottsdale, AZ 85259, USA
    J Clin Oncol 25:3124-9. 2007
    ..To evaluate the outcome of patients with limited-stage small-cell lung cancer (L-SCLC) treated with cisplatin and etoposide (PE), early prophylactic cranial irradiation (PCI), and high-dose twice-daily thoracic radiotherapy (bid RT)...
  11. ncbi Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51
    David M Kurtz
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Leuk Lymphoma 48:1290-8. 2007
    ....
  12. ncbi Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942
    Michael G Haddock
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:2567-72. 2007
    ..A phase II study was conducted to determine the efficacy and toxicity of radiotherapy with concomitant gemcitabine and cisplatin for patients with locally advanced pancreatic adenocarcinoma...
  13. ncbi Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer
    Amanda C Ashley
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:670-7. 2007
    ..Efficacy and toxicity of oxaliplatin (Eloxatin; Sanofi-Aventis, Paris, France) combined with irinotecan (IROX) were examined in 383 patients enrolled on the IROX arm of Intergroup Study N9741...
  14. ncbi The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:363-8. 2007
    ....
  15. ncbi Stool DNA and occult blood testing for screen detection of colorectal neoplasia
    David A Ahlquist
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 149:441-50, W81. 2008
    ..Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting...
  16. ncbi A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma
    Emilian Racila
    Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa 52242, USA
    Clin Cancer Res 14:6697-703. 2008
    ..The purpose of this study was to explore the relationship between the C1qA([276]) polymorphism and the clinical response to rituximab in patients with follicular lymphoma...
  17. ncbi Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Gastrointest Cancer 38:87-94. 2007
    ..To determine the maximum tolerated dose (MTD) and efficacy of pemetrexed and gemcitabine in patients with either biliary tract or gallbladder carcinoma...
  18. ncbi Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-
    Steven R Alberts
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 28:853-8. 2010
    ..However, the merits of this approach need to be established with a phase III trial...
  19. ncbi Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1
    Charles L Loprinzi
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Clin Oncol 28:641-7. 2010
    ..Hot flashes are a common problem for which effective and safe treatments are needed. The current trial was conducted on the basis of preliminary promising data that pregabalin decreased hot flashes...
  20. ncbi Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426
    Alex A Adjei
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 28:614-9. 2010
    ....
  21. ncbi Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147
    Aminah Jatoi
    Mayo Clinic, Rochester, MN 55905, USA
    Oncology 77:120-3. 2009
    ..The objective of this study was to identify clinical predictors of severe rash in the hope of utilizing such factors in the design of future rash palliative and prevention trials...
  22. ncbi Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8
    Ann E Kearns
    Mayo Clinic Rochester, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 18:321-8. 2010
    ..The purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer...
  23. ncbi Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA
    Debra L Barton
    Mayo Clinic and Mayo Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 18:179-87. 2010
    ..This pilot trial sought to investigate whether any of three doses of American ginseng (Panax quinquefolius) might help cancer-related fatigue. A secondary aim was to evaluate toxicity...
  24. ncbi Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831
    Michele Y Halyard
    Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
    J Clin Oncol 27:2638-44. 2009
    ..To assess whether trastuzumab (H) with radiotherapy (RT) increases adverse events (AEs) after breast-conserving surgery or mastectomy...
  25. ncbi Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
    Stephanie L Hines
    Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
    Breast Cancer Res Treat 117:603-9. 2009
    ..Patients in the upfront arm were slightly more likely to report limb edema, fatigue, fever, nausea and jaw osteonecrosis(1%). Upfront zoledronic acid prevents bone loss in postmenopausal women with BC starting letrozole after tamoxifen...
  26. ncbi Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis
    Aditya Bardia
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Menopause 16:477-83. 2009
    ..Various nonestrogenic therapies have been found to be effective in mitigating hot flashes, but it has been unclear whether the efficacy varies by whether women have had breast cancer and/or were taking tamoxifen...
  27. ncbi Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB)
    Andrea L Cheville
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Support Care Cancer 17:451-60. 2009
    ..Lidocaine patches reduce neuropathic pain from herpes zoster but their benefits for persistent cancer-related postsurgical incisional pain remain unclear...
  28. ncbi Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer
    Stephanie L Hines
    Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 27:1047-53. 2009
    ..Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer...
  29. ncbi Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Gastrointest Cancer 38:10-4. 2007
    ..Currently no effective therapies exist for patients with advanced or metastatic HCC. KW-2189, a DNA minor groove-binding agent, has shown promising activity against HCC in preclinical evaluations...
  30. ncbi A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study
    Svetomir N Markovic
    Melanoma Study Group, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 31:573-9. 2008
    ..To improve the clinical and immunologic efficacy of therapy without compromising patient safety, we performed a further dose escalation trial in patients with metastatic melanoma...
  31. ncbi Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group
    Grace K Dy
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Thorac Oncol 1:211-7. 2006
  32. ncbi Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial
    Michael G Haddock
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:1255-9. 2007
    ..To evaluate patient assessment of long-term effect of pelvic radiotherapy on bowel function...
  33. ncbi Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group
    A Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 17:29-34. 2006
    ..We therefore undertook this phase II study to test this first-line combination in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia...
  34. ncbi Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 23:9243-9. 2005
    ..The use of neoadjuvant chemotherapy to improve the likelihood of resection in disease that is not optimally resectable has not been as well studied...
  35. ncbi Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium
    Harry J Long
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Gynecol Oncol 100:501-5. 2006
    ..The North Central Cancer Treatment Group Phase III trial compared efficacy of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) with doxorubicin plus cisplatin (AC) for patients with advanced endometrial cancer...
  36. ncbi Prospective study of quality of life in adults with newly diagnosed high-grade gliomas
    Paul D Brown
    Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Neurooncol 76:283-91. 2006
    ..To assess baseline quality of life (QOL) and its prognostic importance for adults with newly diagnosed high-grade gliomas, we analyzed QOL and outcome data prospectively collected in three phase II high-grade glioma protocols...
  37. ncbi A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival
    Paul D Brown
    Division of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Neurosurgery 57:495-504; discussion 495-504. 2005
    ..001), and greater extent of resection (P < 0.001). CONCLUSION: Baseline QOL was predictive of QOL over time. Gross total resection was associated with longer survival and improved QOL over time for patients with high-grade gliomas...
  38. ncbi The prevalence of weight concerns in a smoking abstinence clinical trial
    Matthew M Clark
    Mayo Clinic Mayo Building W11, 200 First Street, SW, Rochester, MN 55905, USA
    Addict Behav 31:1144-52. 2006
    ..Additionally, being weight concerned may impact the short-term success rates of stopping smoking using pharmacotherapy...
  39. ncbi Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer
    Cynthia X Ma
    Department of Oncology and Medicine, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5929-37. 2005
    ..CONCLUSION: Pemetrexed and gemcitabine administered as outlined for schedule A met the protocol-defined efficacy criteria, was less toxic compared with the other treatment schedules, and should be further evaluated...
  40. ncbi A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study
    G K Dy
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 16:1811-6. 2005
    ....
  41. ncbi PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study
    S R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905
    Ann Oncol 16:1654-61. 2005
    ..This randomized phase II study determined the tumor response rate (RR) for PS-341 alone and the 6-month survival and RR for the combination of gemcitabine and PS-341 in patients with metastatic pancreatic adenocarcinoma...
  42. ncbi Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Thomas E Witzig
    Mayo Clinic College of Medicine, Stabile 628, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5347-56. 2005
    ..This study tested whether temsirolimus (previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase that regulates cyclin D1 translation, could produce tumor responses in patients with MCL...
  43. ncbi Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial
    Charles L Loprinzi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 56301, USA
    Cancer 104:176-82. 2005
    ..Secondary research goals were to evaluate toxicities, tolerability, and quality of life associated with this shark cartilage product...
  44. ncbi Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:2349-54. 2005
    ..No difference in survival was identified between the two arms. The current analysis examined the relation between age and outcome for patients treated during this trial...
  45. ncbi Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial
    Patrick A Burch
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Clin Oncol 28:195-200. 2005
    ..This 2-stage, phase II cooperative group trial examined the efficacy and toxicity of 1000 mg/m2 gemcitabine plus 25 mg/m2 cisplatin weekly for 3 weeks and repeated every 28 days for patients with previously treated metastatic breast cancer...
  46. ncbi Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials
    Michelle R Mahoney
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 23:9275-81. 2005
    ..We assessed the utility of the RAE data collected, relative to the volume...
  47. ncbi Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group
    K F Giordano
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 17:652-6. 2006
    ..CONCLUSIONS: The regimen docetaxel and capecitabine shows activity in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. This regimen merits further study...
  48. ncbi Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7
    Charles L Loprinzi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:1409-14. 2006
    ..This current trial compared a single intramuscular dose of medroxyprogesterone acetate (MPA), depot preparation, versus daily oral venlafaxine as treatment for hot flashes...
  49. ncbi Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4)
    Michele Y Halyard
    Mayo Clinic, Scottsdale, AZ, USA
    Int J Radiat Oncol Biol Phys 67:1318-22. 2007
    ..This multi-institutional, double-blind, placebo-controlled trial was conducted to provide definitive evidence of this mineral's palliative efficacy...
  50. ncbi A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Urology 69:289-94. 2007
    ..Tomatoes are rich in lycopene. This study explored the efficacy of a lycopene-rich tomato product in androgen-independent prostate cancer and the reasons patients participated in an "alternative medicine" study...
  51. ncbi Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention
    Ivana T Croghan
    Nicotine Research Center, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:186-95. 2007
    ..To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention...
  52. ncbi Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5
    Charles L Loprinzi
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:308-12. 2007
    ..No data have been available to address whether the combination of both agents would more effectively alleviate hot flashes, compared with gabapentin alone, in patients with inadequate hot flash control with an antidepressant alone...
  53. ncbi Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma
    Paul D Brown
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:5427-33. 2006
    ..To assess the cognitive performance of high-grade glioma patients, prospectively collected cognitive performance data were analyzed...
  54. ncbi Can complementary and alternative medicine clinical cancer research be successfully accomplished? The Mayo Clinic-North Central Cancer Treatment Group experience
    Debra L Barton
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Soc Integr Oncol 4:143-52. 2006
    ..Well-designed and adequately powered studies can be implemented, and large numbers of patients can be accrued. The resulting research evaluations can be published in peer-reviewed medical journals...
  55. ncbi Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group
    Jan C Buckner
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:3871-9. 2006
    ....
  56. ncbi Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Am J Ther 13:291-7. 2006
    ..Quality-of-life measures did not show any differences between the 2 groups. This study showed no evidence of benefit from flutamide as a chemoprevention agent in men with HGPIN...
  57. ncbi Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial
    Alvaro Moreno-Aspitia
    Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA
    Cancer 107:767-72. 2006
    ..Limited efficacy and increased toxicity were observed in the current Phase II trial...
  58. ncbi Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1
    Barbara A Pockaj
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 24:2836-41. 2006
    ..CONCLUSION: This trial failed to provide any evidence that black cohosh reduced hot flashes more than the placebo...
  59. ncbi A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer
    Julian R Molina
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer Invest 24:382-9. 2006
    ..6 months and 7.5 months, respectively. CONCLUSION: This second-line treatment regimen of irinotecan and docetaxel in NSCLC patients has shown activity, but can not be recommended over single-agent regimens because of significant toxicity...
  60. ncbi Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer
    Julian R Molina
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 29:246-51. 2006
    ..9%. CONCLUSION: This regimen has shown similar antitumor activity to that achieved with standard therapy. Because of unacceptable toxicity and cost, we do not recommend this regimen in a palliative setting...
  61. ncbi Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer
    Steven E Schild
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 65:1106-11. 2006
    ..This trial was performed to determine the maximum tolerated dose (MTD) of radiation that can be administered with carboplatin and paclitaxel...
  62. ncbi Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial
    Steven R Alberts
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 103:111-8. 2005
    ....